Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2549-2556

  Adams, M ^a   Borysiewicz, L ^b   Fiander, A ^b   Man, S ^b   Jasani, B ^b   Navabi, H ^a   Lipetz, C ^a   Evans, A S ^b   Mason, M ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; ENAMINE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EARLY CANCER; FEMALE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; VIRUS ONCOGENE; WART VIRUS;

ADOPTIVE TRANSFER; ANTIBODIES, VIRAL; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; RECOMBINATION, GENETIC; SAFETY; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0035925582     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00488-6     Document Type: Conference Paper

References (54)

1. Estimates of the world wide mortality from eighteen major cancers in 1985. Implications for prevention and projection of future burden
2. Papilloma viruses in human cancer
3. Human papillomavirus and cervical cancer: Epidemiological evidence
4. Detection of human papilloma virus infections and possible clinical implications
5. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis
6. HPV oncoprotein function
7. The Human Papilloma viruses
8. Difference in prevalence of human papilloma virus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intra-epthelial neoplasia
9. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papilloma virus genotypes using polymerase chain reaction
10. In Current views on the epidemiology of HPV and cervical cancer
11. Epidemiological evidence showing that human papilloma virus infection causes most cervical intraepithelial neoplasia
12. Trends in Mortality from cervical cancer in the Nordic countries: Association with organised screening programs
13. Effect of organised screening on the risk of cervical cancer. Evaluation of screening activity in Iceland
14. A case control study of cervical cancer screening in the NE Scotland
15. A screening programme for cervical cancer that worked
16. Survival of European Women with Gynaecological tumours during the period 1978-1989
17. Cervical dysplasia in HIV seropositive women - Role of human papilloma virus infection and immune status
18. Cellular immunodeficiciency enhances the progression of human papilloma-virus associated cervical lesions
19. Genital papilloma virus infection and cervical dysplasia-opportunistic complications of HIV infection
20. Human papilloma virus and lower genital neoplasia in renal transplant patients
21. Human papilloma virus in the immunosuppressed
22. Serological responses to HPV16 in cervical dysplasia and neoplasia. Correlation of antibodies to E6 with cervical cancer
23. Progression from papilloma to carcinoma is accompanied by changes in antibody response to papilloma virus proteins
24. Role of HLAA motifs in identification of potential epitopes in human papilloma virus type 16 E6 and E7 proteins
25. Vaccination with cytoxic T lymphocyte epitope containing peptide protects against a tumour induced by human papilloma virus type 16 cells
26. Immunisation against papilloma virus type 16 tumour cells with recombinant vaccinia viruses expressing the E6 and E7
27. Prophylactic and therapeutic vaccination against mucosal papilloma virus
28. Treatment of established tumours with a novel vaccine enhances major histocompatibility class 2 presentation antigen
29. Construction and characterisation of recombinant vaccinia virus expressing human papilloma virus proteins for immunotherapy of cervical cancer
30. PCR based detection of genital HPV genotypes. An update and future perspectives
31. Complications of smallpox vaccination 1968. National surveillance in the United States
32. Use of recombinant vaccinia viruses to examine cytotoxic T lymphocyte recognition of individual viral proteins.1
33. A recombinant vaccinia virus encoding human papilloma virus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer
34. TM A Modified Vaccinia virus carrying HPV 16 and 18 E6 and E7 Proteins induces potent immunity in women with early cervical cancer
35. Constitutive and enhanced expression from CMV major IE promoter in a defective adenovirus vector
36. Human cytomegalovirus specific cytotoxic T cells recognise the 72Kd immediate early proteins and glycoprotein B in recombinant vaccinia viruses
37. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and anti-tumour responses
38. Enhancing efficacy of recombinant-cancer vaccines with prime/boost regimens that use two different vectors
39. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intra epithelial neoplasia grade 3
40. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes
41. Analysis of MHC class 1 and 2 expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions
42. Analysis of cytokine profiles in patients with human papilloma virus-associated neoplasms
43. Induction of antigen-specific T cell anergy: An early event in the course of tumour progression
44. Use of fluoresceinated HLA-A*0201/HPV 16 E7 peptide complexes to isolate rare human CTL recognising endogenous HPV antigens
45. Immunocompetent for imunotherapy? A study of the immunocompetence of cervical cancer patients
46. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentation of multiple haemopoetic lineages in vivo
47. Bone marrow-derived dendritic cells pulsed with sythetic tumour peptides elicit protective and therapeutic anti-tumour immunity
48. Vaccination of melanoma patients with peptide or tumour lysate pulsed dendritic cells
49. In vitro evaluation of cervical tumour lysate as a source of antigen for dendritic cell (DC) based immunotherapy of cervical cancer
50. Vaccination with Mage-3A1 peptide pulsed mature monocyte derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced Melanoma
51. Rapid generation of broad T cell immunity in humans after a single injection of mature dendric cells
52. Interleukin 10 treated human dendritic cells induce a melanoma-antigen-specific anergy in CD 8 + T cells resulting in a failure to lyse tumour cells